Logo - springer
Slogan - springer

Biomedical Sciences - Cancer Research | Molecular Targeting in Oncology

Molecular Targeting in Oncology

Kaufman, Howard L., Wadler, Scott, Antman, Karen (Eds.)

2008, XVI, 728 p.

A product of Humana Press
Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$209.00

(net) price for USA

ISBN 978-1-59745-337-0

digitally watermarked, no DRM

Included Format: PDF

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$269.00

(net) price for USA

ISBN 978-1-58829-577-4

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$269.00

(net) price for USA

ISBN 978-1-61737-653-5

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Five sections cover the most important elements of drug development: Drugs, Strategies, Disease Sites, Classes, and Challenges
  • Sections present different perspectives on how targeted therapeutics are being evaluated

In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.

The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more.  Comprehensive and cutting-edge, Molecular Targeting in Oncology is an essential reference for those working in the field.

Content Level » Research

Keywords » antibody - cancer - cancer prevention - cancer therapy - cancer treatment - carcinoma - cell - cytokine - melanoma - ovarian cancer - pancreatic cancer - prevention - prostate cancer - targeted therapy - vaccine

Related subjects » Cancer Research - Chemistry - Oncology & Hematology - Pharmacology & Toxicology

Table of contents 

Table of Contents Section 1 General Strategies for Molecular Targeting in Oncology Chapter 1 The Cell Cycle: Therapeutic Targeting of Cell Cycle Regulatory Components and Effector Pathways in Cancer Chad D. Knights and Richard G. Pestell Chapter 2 mTOR: Properties and Therapeutics John B. Easton and Peter J. Houghton Chapter 3 Ras/Raf/MEK Inhibitors Joseph A. Sparano Chapter 4 17AAG: Targeting the Molecular Chaperone Heat Shock Protein 90 Len Neckers and Percy Ivy Chapter 5 The Cancer Epigenome: Can it be targeted for therapy? Sam Thiagalingam and Douglas V. Faller Section 2 Molecular Targeting for Specific Disease Sites Chapter 6 Molecular targeting in upper gastrointestinal malignancies Scott Wadler Chapter 7 Molecular Targeting of Colorectal Cancer: An Idea Whose Time Has Come Mark L. Sundermeyer, Alfonso Bellacosa, and Neal J. Meropol Chapter 8 Molecular Targeting in Hepatocellular Carcinoma Jonathan D. Schwartz. and Josep M. Llovet Chapter 9 Molecularly Targeted Therapy in Pancreatic Cancer Anupama Goel and Peter Kozuch Chapter 10 Untargeted Use of Targeted Therapy: A Dilemma in Non-Small Cell Lung Cancer Cheryl Ho, Angela M. Davies, Primo N. Lara, O. Gautschi, P.C. Mack, Paul H. Gumerlock and David R. Gandara Chapter 11 Molecular Targeting in Oncology: Renal Cell Cancer Olwen Hahn and Walter Stadler Chapter 12 Targeted Therapies for Prostate Cancer Elisabeth I. Heath and Michael A. Carducci Chapter 13 Molecular Targets in Ovarian Cancer and Endometrial Cancer Nilofer S. Azad, Gisele Sarosy, and Elise C. Kohn Chapter 14 Targeted Therapy for Breast Cancer Deena M. Atieh and Linda T. Vahdat Chapter 15 Melanoma Akshay Gupta and John M. Kirkwood Section 3 Classes of Drugs for Molecular Targeting in Oncology Chapter 16 Antibody Therapy of Cancer Hossein Borghaei, Liat Binyamin, Igor Astsaturov, and Louis M. Weiner Chapter 17 Nucleic Acid Therapies for Cancer Treatment Dan T. Vogl and Alan M. Gewirtz Chapter 18 Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy Takafumi Nakamura and Stephen J. Russell Chapter 19 Vaccines as Targeted Cancer Therapy Miguel-Angel Perales, Jedd D. Wolchok and Howard L. Kaufman Chapter 20 Cytokine based therapy for cancer Henry B. Koon and Michael B. Atkins Chapter 21 Cyclooxygenase-2 (Cox-2) as a Target for Cancer Prevention and Treatment Monica Bertagnolli, Jaye L. Viner, and Ernest T. Hawk Section 4 Specific Drugs for Molecular Targeting in Oncology Chapter 22 Imatinib Mesylate (Gleevec) and the emergence of chemotherapeutic drug-resistant mutation Gerald V. Denis Chapter 23 Development of a Targeted Treatment for Cancer: The Example of C225 (Cetuximab) John Mendelsohn Chapter 24 VEGF Inhibition for Cancer Therapy Shermini Saini and Herbert Hurwitz Chapter 25 Somatostatin analogue therapy Manish C. Champaneria, M.D., Irvin M. Modlin, M.D., Ph.D., D.Sc., Igor Latich, M.D., Jan Bornschein, Ignat Drozdov, Mark Kidd, Ph.D. Section 5 Challenges in Molecular Targeting in Oncology Chapter 26 Patient Selection for Rational Development of Novel Anticancer Agents Grace K. Dy and Alex A. Adjei Chapter 27 Clinical Trial Design with Targeted Agents Sarita Dubey and Joan H. Schiller Chapter 28 How to define treatment success or failure if tumors don't shrink: Consequences for trial design. JJEM Kitzen, MJA de Jonge, and J Verweij Chapter 29 Molecular Imaging in Oncology Lalitha Shankar, Anne Menkens, and Daniel C. Sullivan Chapter 30 Combinations of Molecular Targeted Therapies - Opportunities and Challenges Helen X. Chen and Janet E. Dancey Chapter 31 Preclinical Development of Molecularly Targeted Agents

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Cancer Research.